< BACK Highlights from IFPA 2024 Jun 28, 2024 iPROLEPSIS at IFPA 2024 The 7th World Psoriasis & Psoriatic Arthritis Conference, held on June 27-29, 2024, brought together leading experts and researchers to discuss the latest advancements in psoriasis and psoriatic arthritis. Dr Laura Coates from the University of Oxford discussed the potential to prevent psoriatic arthritis, including the work being done in iPROLEPSIS and HIPPOCRATES IMI. 1/6 PREVIOUS NEXT

< BACK Highlights from PETRA 2024 Jul 1, 2024 The iPROLEPSIS Exergames Introduced at PETRA 2024 The iPROLEPSIS Exergames were introduced and received very positively by the audience at PETRA 2024, a scientific interdisciplinary conference held on 26-28 June 2024 in Crete, Greece. Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes Abstract: Serious Games (SGs) offer significant potential in healthcare for disease assessment and intervention, enhancing patients’ quality of life. Exercise SGs, or Exergames, promote physical activity and mobility in a gamified environment, encouraging tailored exercises based on individual abilities and needs. Here, within the Horizon Europe iPROLEPSIS project that targets Psoriatic Arthritis (PsA), we describe the design process of Exergames to address PsA symptoms, including morning stiffness, impaired finger/hand and wrist functionality, and motor asymmetry. From a methodological point of view, the storyboarding technique was adopted to facilitate the visualization of the proposed Exergame scenarios, including the graphical user interface, interactive game elements, narratives, characters, and contexts related to the PsA condition. This approach has been implemented within an agile game development methodology, which includes gathering feedback early on to iteratively refine both the game ideas and prototype. Informed by the results of the game design via two agile sessions incorporating 25 participants (PsA patients, clinicians, technology developers, facilitators/observers), the current efforts are focused on developing the game prototypes and corresponding mock-ups, preparing them for upcoming clinical validation trials. The Exergames development lays the groundwork for an innovative framework to improve gross and fine motor symptoms in PsA patients. This framework could inform healthcare providers and policymakers about its potential inclusion in routine PsA management. Read the full publication: https://dl.acm.org/doi/10.1145/3652037.3663939 1/3 PREVIOUS NEXT

< BACK iPROLEPSIS Sensorimotor Games Presented at DSAI 2024 Nov 20, 2024 Innovative digital games designed to support people with Psoriatic Arthritis presented at an international ICT conference. The iPROLEPSIS project coordinator, Prof. Leontios Hadjileontiadis, presented the iPROLEPSIS Sensorimotor Games at the 11th International Conference on Software Development and Technologies for Enhancing Accessibility and Fighting Info-exclusion (DSAI 2024) . The conference was held from 13–15 November at Khalifa University in Abu Dhabi, United Arab Emirates (UAE). The Sensorimotor Games are interactive digital applications designed for more than just entertainment. They combine enjoyment with skills training, social impact, and health improvement. As part of a personalised game suite, these games aim to support people living with Psoriatic Arthritis (PsA), offering a unique approach to enhancing their quality of life. DSAI is a leading international forum focused on accessible and usable Information and Communication Technologies (ICT). The conference provided an excellent platform to share progress on the iPROLEPSIS project and highlight its innovative approach to digital healthcare solutions. 1/2 PREVIOUS NEXT

< BACK Unveiling the Future of Psoriatic Arthritis Care: Insights from Dr Laura Coates Mar 19, 2024 Exploring the iPROLEPSIS Project and Innovations in Digital Health Technologies for Enhanced Patient Care Dr Laura Coates , a researcher and clinician from the University of Oxford , guides through the research and clinical studies of the iPROLEPSIS project. In her own words: "It’s my pleasure to be leading all of the clinical studies within the iPROLEPSIS Consortium. We're focused on developing and testing apps and digital health technologies to enhance the care for patients with psoriatic arthritis ." Discover how these innovative tools aim to predict and manage psoriatic arthritis flares, identify at-risk individuals, and empower patients to take control of their health. Dr Coates elaborates on the various aspects of the research, including the development of apps that could foresee a flare, identify triggers, and even provide support for stress management and activity. https://www.youtube.com/watch?v=nYPtH0jb0yo Screenshot 2024-03-19 123331.png Screenshot 2024-03-19 123331.png 1/1 PREVIOUS NEXT

< BACK Advancing Psoriatic Arthritis: Rheumatologist Ilja Tchetverikov's Insights on iPROLEPSIS May 22, 2024 Exploring Innovative Approaches to Disease Management and Patient Care in Psoriatic Arthritis" Ilja Tchetverikov , a rheumatologist and project partner from the CICERO Foundation (the Netherlands), provides insights into the iPROLEPSIS project's endeavours. He emphasises the need for a deeper understanding of psoriatic arthritis , a chronic inflammatory condition impacting various body parts due to immune system disturbances. I. Tchetverikov highlights the project's focus on investigating disease progression factors and developing non-invasive measurement tools . “Everybody can measure anything, but then you have to know what you're measuring. The whole idea of the project is that we combine two strengths. One of them is providing and developing a technical solution on how to measure the disease activity. And from the other side, we are going to label the data coming in from the system, from the clinical point of view. So we will be able to say whether or not some people have a low or high level of disease activity. So it's one part of the investigation. The other part of the investigation is to see whether other factors, which are already known to influence the whole system of your human body, like stress factors and some, for instance, gut microbiome composition, can also change during the course of the disease and how they are influencing the course of the disease itself,” states Ilja Tchetverikov . Through a collaborative effort integrating clinical expertise and technical innovation, the project aims to assess disease activity levels and explore external factors accurately. https://www.youtube.com/watch?v=PcUHfHsWSVs iPROLEPSIS interview.png iPROLEPSIS interview.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at BIOSTEC 2026 Mar 16, 2026 Presenting iPROLEPSIS at an international forum on biomedical engineering and health technology The 19th International Joint Conference on Biomedical Engineering Systems and Technologies (BIOSTEC 2026) took place in Marbella, Spain from 2 to 4 March 2026. The event brought together researchers, technology developers, and industry representatives working in biomedical engineering and healthcare technologies. iPROLEPSIS was represented at the event by project partner PLUX. The project was presented to an international audience, helping to raise its visibility among stakeholders interested in digital health and innovative medical technologies. PLUX also highlighted the importance of multisensor biosignal acquisition and the value of combining different physiological signals to support more comprehensive health research and real-world healthcare applications. iProlepsis BIOSTEC 2.jpg 20260303_111530.jpg IMG_6609.jpg iProlepsis BIOSTEC 2.jpg 1/4 PREVIOUS NEXT

< BACK AI-Driven Early Prediction and Personalised Care | iPROLEPSIS, AI-PROGNOSIS & REBECCA Mar 3, 2026 A joint video highlighting how digital biomarkers and real-world data support patient-centred healthcare across three disease areas What happens when a disease enters someone’s life and changes everything? Millions of people live with chronic conditions that shape their daily routines – often in ways that are invisible to others. Early diagnosis, timely intervention and more effective care can make a profound difference. In a new joint video developed with support from the European Commission’s Booster initiative, the EU-funded projects iPROLEPSIS , AI-PROGNOSIS and REBECCA present a shared vision for patient-centred artificial intelligence in healthcare. The video highlights how AI and digital biomarkers can enable earlier prediction, continuous monitoring and more personalised care across three disease areas: Psoriatic arthritis (iPROLEPSIS) Parkinson’s disease (AI-PROGNOSIS) Breast cancer survivorship (REBECCA) By integrating real-world behavioural data, wearable sensor signals and patient-reported information, the projects demonstrate how complex health data can be transformed into actionable clinical insights. These AI-driven approaches aim to strengthen clinical decision-making while keeping patients at the centre of care. The video reflects the projects’ commitment to developing trustworthy, responsible and co-designed AI solutions that respond to real clinical and patient needs. Watch the video here: https://www.youtube.com/watch?v=hWu3bPzQBiA To learn more, visit: iPROLEPSIS – https://www.iprolepsis.eu AI-PROGNOSIS – https://www.ai-prognosis.eu REBECCA – https://www.rebeccaproject.eu Screenshot 2026-03-02 115452.png Screenshot 2026-03-02 115452.png 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search What is psoriatic arthritis? See related Handbook section PREVIOUS NEXT

< BACK Dynamic Difficulty Adjustment in Psoriatic Arthritis Serious Games Using Learning-Driven Policies Sep 1, 2026 New iPROLEPSIS publication presents machine learning approach to personalise game difficulty based on patient condition A new iPROLEPSIS publication presents a system that automatically adjusts game difficulty to match each patient's changing condition during therapeutic gameplay. The study proposes a Dynamic Difficulty Adjustment (DDA) system using machine learning – specifically Reinforcement Learning and Multi-Armed Bandits –to personalise how two serious games challenge players: Mr. Blue Sky, targeting wrist mobility, and The Kite, focusing on breathing and relaxation. Data were collected from 32 participants playing these games, tracking gameplay performance, physiological signals (heart rate and stress), and self-reported relaxation levels. Machine learning algorithms learned which difficulty progression works best based on how patient condition changes during play. Results showed that the best-performing strategies began gameplay at medium difficulty, then adjusted downward. In a feasibility pilot with six psoriatic arthritis patients, this automatic adjustment produced coherent therapeutic progressions while accounting for the fluctuating nature of patient symptoms. The system demonstrates how machine learning can support personalised rehabilitation, continuously adapting game challenges to patient needs rather than using fixed difficulty levels. Read the full publication: https://ieeexplore.ieee.org/document/11663158 iPROLEPSIS_Dynamic Difficulty adjustment in PsA publication.png iPROLEPSIS_Dynamic Difficulty adjustment in PsA publication.png 1/1 PREVIOUS NEXT

< BACK Season's Greetings from iPROLEPSIS Dec 21, 2023 Merry Christmas and Happy New Year! No updates and announcements, simply warmth, joy, health and peace from the iPROLEPSIS consortium to all our community! Thank you for being a part of our journey. merry (1).png merry (1).png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at IEEE-EMBS BSN 2025 Nov 6, 2025 Showcasing iPROLEPSIS at a leading international conference on body sensor research The IEEE-EMBS International Conference on Body Sensor Networks (IEEE-EMBS BSN 2025) took place in Los Angeles, USA, from 3–5 November 2025. The conference brings together researchers, clinicians, and industry representatives working on body sensor technologies and their applications in health and biomedical research. iPROLEPSIS was showcased at the event by project partner PLUX , which hosted a dedicated booth. The project was presented to an international audience, increasing its visibility within the body sensor and digital health research community. IEEE EMBS 2025 2.HEIC IEEE EMBS 2025 1.HEIC IEEE EMBS 2025 3.HEIC IEEE EMBS 2025 2.HEIC 1/3 PREVIOUS NEXT

< BACK iPROLEPSIS at GRAPPA 2025: Advancing Digital Tools for Psoriatic Arthritis Care Jul 18, 2025 Exploring how digital biomarkers can support hand function assessment in real-world settings iPROLEPSIS participated in the GRAPPA Annual Meeting 2025 , held on 10–12 July in Bogotá, Colombia. Vasilis Charisis (Aristotle University of Thessaloniki – AUTH) presented an overview of the project’s key objectives and emerging results. The talk highlighted how digital biomarkers – captured via smartphone typing dynamics and video-based motor tasks – can support the assessment of hand function in real-world conditions. The session reached approximately 350 stakeholders, including clinicians, researchers, and industry representatives, helping raise awareness of iPROLEPSIS and its goals within the psoriatic disease community. 2.jpg 1.jpg 3.jpg 2.jpg 1/3 PREVIOUS NEXT